The Perception of New Clinical Entities. Synergism Between Clinical Research and Marketing Research in Successful Drug Development
Brbel Matiaske (I+G) Germany Raf De Wilde (Janssen Pharmaceutica) Belgium
BACKGROUND AND MAIN OBJECTIVES
The pharmaceutical industry has experienced a global increase in the duration and costs of the clinical development of drugs, which has been aggravated by restrictive pricing policies in almost all countries. This situation and the large gap between the small number of NCEs (New Chemical Entity) which have been introduced in their first market world-wide (for example, in 1995 n = 39, according to SCRIP Review)...